A potent inhibitor of JAK2 that also inhibits the JAK2V617F mutant enzyme (IC50s for both enzymes ~ 0.5 nM); orally bioavailable with a long half-life in vivo, suppressing leukemic cell spreading and splenomegaly in JAK2V617F cell-driven disease in mice
Size
5 mg
Concentration
n/a
Applications
n/a
Other Names
biochemical cancer inhibitor signal transduction kinase protein kinase selective potent JAK2 NVPBSD805 inhibit JAK2V617F V617F mutant enzyme serine threonine tyrosine ATP-competitive ATPcompetitive orally bioavailable long half-life halflife in vivo suppressing suppress leukemic leukemia cell spread splenomegaly disease mice mouse recombinant human erythropoietin-induced polycythemia extramedullary extra medullary erythropoiesis rat